Prudential Jennison Health Sciences Class R (PJHRX)

46.59
Net Asset Value
+0.22%
1 Day
+5.62%
Year-to-Date
Overall Morningstar Rating
Health
Style or Category
No Load
Sales Expenses
1.73%
Expense Ratio
Above Average
Morningstar Risk Rating™
Investment Objective The investment seeks long-term capital appreciation. The fund seeks investments whose prices will increase over time. It normally invests at least 80% of its investable assets in equity and equity-related securities of companies within the health sciences sector- such as pharmaceutical companies- biotechnology companies- medical device manufacturers- healthcare service providers and health maintenance organizations (HMOs) and other companies that derive at least 50% of their assets- revenues or profits from operations in the healthcare sector. The fund is non-diversified.

Performance

1 month+4.19% 3 years+1.87%
3 months+2.27% 5 years+15.39%
1 year+20.84% Since inception+17.53%
Data through --

Peer Comparisonvs. Health

 PJHRXCategory
Performance 5-yr return+15.39%+14.29%
Expense ratio1.73%1.29%
Risk 5 year sharpe ratio0.750.89
Net assets$2.2B$2.9B
Average market cap$11.4B$9.8B
Average P/E--22.0
Portfolio turnover27%27%

There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.

Fund Management and Purchase Info

Fund familyPrudential Funds (PGIM Investments)
Fund manager & tenureDavid Chan / 18 Years
Minimal initial investment$0.00
Minimum IRA investment--

Holdings

U.S. stock91.25%
International stock6.23%
Cash1.78%
Fixed income0.58%
Other0.16%
Top 5 Sectors
Portfolio weighting
Business service --
Consumer goods --
Consumer service --
Energy --
Financial service --
Top 10 Holdings
Portfolio weighting
UNH UnitedHealth7.31%
BMRN Biomarin Pharmaceutical Inc5.60%
ILMN Illumina Inc3.69%
SAGE SAGE Therapeutics Inc3.62%
HUM Humana Inc3.15%
ASMB Assembly Biosciences Inc3.14%
SRPT Sarepta Therapeutics Inc3.12%
AGN Allergan3.05%
BLUE bluebird bio Inc2.87%
CNC Centene Corp2.37%